It was reported on Tuesday that the European Commission has granted final approval to US-based companies Mylan (NASDAQ: MYL) and Pfizer Inc (NYSE: PFE) for the proposed combination of their Upjohn business.
The European Commission offered conditional approval in April 2020 that was subject to the divestiture of certain of Mylan's products in Europe.
The European Commission approved the proposed divestiture buyers and Mylan signed the contract with those customers on terms that the European Commission has accepted. Both firms have already received approval from the Australian Competition and Consumer Commission and the New Zealand Commerce Commission related to combining this business.
Clene Inc closes registered direct offering of common stock to existing shareholders
Insmed's ARIKAYCE sNDA granted priority review by FDA
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
MaaT Pharma receives negative CHMP trend vote for MaaT013
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis